menu search

ACIU / AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why

AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why
AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases. Read More
Posted: Sep 5 2023, 14:17
Author Name: Zacks Investment Research
Views: 112169

ACIU News  

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

By Zacks Investment Research
October 24, 2023

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

Here is how AC Immune (ACIU) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year. more_horizontal

AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

By Zacks Investment Research
October 20, 2023

AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the k more_horizontal

AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why

By Zacks Investment Research
September 5, 2023

AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why

AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for more_horizontal

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

By GlobeNewsWire
September 5, 2023

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 more_horizontal

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
August 4, 2023

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

AC Immune (ACIU) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share more_horizontal

Why Shares of AC Immune Jumped This Week

By The Motley Fool
June 30, 2023

Why Shares of AC Immune Jumped This Week

AC Immune is a clinical-stage biotech with 16 programs in its pipeline. It is attempting to develop an Alzheimer's disease vaccine. more_horizontal

Trading Penny Stocks With Limited Capital: 3 Tops Tips

By PennyStocks
June 28, 2023

Trading Penny Stocks With Limited Capital: 3 Tops Tips

The allure of penny stocks is undeniable. Their low price and potential for massive returns create an inviting landscape for individuals, especially t more_horizontal

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

By Market Watch
June 27, 2023

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

AC Immune SA's stock ACIU, +4.21% soared 13% premarket Tuesday, after the Swiss-based biotech said it has received U.S. Food and Drug Administration f more_horizontal


Search within

Pages Search Results: